Menu Search
Equities

Adaptive Biotechnologies Corp

1HM:DUS

Adaptive Biotechnologies Corp

Actions
  • Price (EUR)4.12
  • Today's Change-0.067 / -1.60%
  • Shares traded--
  • 1 Year change+5.14%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 11:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how the immune system detects and treats disease in that patient. It has business around two main areas: clinical assessment of minimal residual disease (MRD) in lymphoid malignancies and immune medicine (IM)-driven drug discovery and development. The MRD business focuses on the use of its highly sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. It comprises its clonoSEQ clinical diagnostic test, offered to clinicians, and its clonoSEQ assay, offered to biopharmaceutical partners, to advance drug development efforts (MRD Pharma).

  • Revenue in USD (TTM)177.28m
  • Net income in USD-195.24m
  • Incorporated2009
  • Employees709.00
  • Location
    Adaptive Biotechnologies Corp1165 Eastlake Ave ESEATTLE 98109United StatesUSA
  • Phone+1 (206) 659-0067
  • Fax+1 (206) 659-0667
  • Websitehttps://www.adaptivebiotech.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.